Literature DB >> 10624363

The value of metastatic screening in early primary breast cancer.

M C Barry1, F Thornton, M Murphy, F Younis, R G Watson.   

Abstract

Up to 25 per cent of patients presenting with "early" breast cancer subsequently develop distant metastases indicating that this group must have occult disseminated disease when initially evaluated. Routine pre-operative haematological and radiological investigation is recommended in order to identify these patients and alter their management accordingly. The aim of this study was to examine the outcome of a pre-operative metastatic screening programme in patients presenting with early breast cancer. Eighty-two patients underwent surgery for stage I-II breast cancer over a 5 yr period from 1990-1995. Before surgery all patients underwent screening tests for metastatic disease. These included a full blood count, liver function tests, chest x-ray, skeletal survey and abdominal ultrasound. Of the 82 patients, metastatic screening significantly altered management in only 1 patient who was found to have asymptomatic lymphangitis carcinomatosa on chest x-ray. The results of this study suggest that the number of patients restaged by screening for metastatic breast cancer may be small and questions the necessity for its routine use in the management of early primary breast cancer.

Entities:  

Mesh:

Year:  1999        PMID: 10624363     DOI: 10.1007/bf02944350

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  22 in total

1.  How far investigations for occult metastases in breast cancer aid the clinician.

Authors:  R Glynne-Jones; T Young; A Ahmed; P J Ell; R J Berry
Journal:  Clin Oncol (R Coll Radiol)       Date:  1991-03       Impact factor: 4.126

2.  Consensus development conference: treatment of primary breast cancer.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-11

3.  The detection of skeletal metastases from carcinoma of the breast.

Authors:  C S Galasko
Journal:  Surg Gynecol Obstet       Date:  1971-06

4.  Value of preoperative bone and liver scans and alkaline phosphatase in the evaluation of breast cancer patients.

Authors:  H S Brar; J F Sisley; R H Johnson
Journal:  Am J Surg       Date:  1993-02       Impact factor: 2.565

Review 5.  ABC of breast diseases. Prognostic factors.

Authors:  W R Miller; I O Ellis; J R Sainsbury; J M Dixon
Journal:  BMJ       Date:  1994-12-10

6.  Preoperative and follow-up procedures on patients with breast cancer.

Authors:  E F Scanlon; M A Oviedo; M P Cunningham; J A Caprini; J D Khandekar; E Cohen; B Robinson; E Stein
Journal:  Cancer       Date:  1980-08-15       Impact factor: 6.860

7.  Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease.

Authors:  M J Duffy; C Duggan; H E Mulcahy; E W McDermott; N J O'Higgins
Journal:  Clin Chem       Date:  1998-06       Impact factor: 8.327

8.  An analysis of imaging studies and liver function tests to detect hepatic neoplasia.

Authors:  T J McGarrity; T Samuels; F A Wilson
Journal:  Dig Dis Sci       Date:  1987-10       Impact factor: 3.199

Review 9.  Diagnostic imaging in cancer.

Authors:  C G Berman; R A Clark
Journal:  Prim Care       Date:  1992-12       Impact factor: 2.907

10.  The clinical value of CEA and CA 15-3 in breast cancer management.

Authors:  E C Coveney; J G Geraghty; F Sherry; E W McDermott; J J Fennelly; N J O'Higgins; M J Duffy
Journal:  Int J Biol Markers       Date:  1995 Jan-Mar       Impact factor: 3.248

View more
  1 in total

1.  Usefulness of staging chest-CT in patients with operable breast cancer.

Authors:  Jung Hee Hong; Jin Mo Goo; Hyeong-Gon Moon; Jung Min Chang; Jong Hyuk Lee; Chang Min Park
Journal:  PLoS One       Date:  2021-02-11       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.